May 15, 2026 Parkinson’s Disease in Women: Research Gaps, Treatment Challenges, and New Hope Through GEM-PD May is Women’s Health Month and in observation, Bio.News sat down with Ragasudha Botta, MBBS, PhD, MMSc, Senior Scientific...
April 25, 2025 Developing digital health technologies for frontotemporal degeneration Frontotemporal degeneration (FTD) is a rare neurodegenerative disease in which patients can present with cognitive, behavioral...
April 2, 2025 C-Path’s Stephenson Appears on Xtalks’ Life Science Podcast to Talk Future of Drug Development in Parkinson’s, Alzheimer’s C-Path's Diane Stephenson recently appeared on the Xtalks Life Science Podcast...
March 10, 2025 C-Path’s Critical Path for Parkinson’s Consortium Welcomes CND Life Sciences C-Path is excited to welcome CND Life Sciences as the newest member of it Critical Path for Parkinson’s (CPP)...
August 12, 2024 C-Path Welcomes CuraSen As Newest CPP Member C-Path is thrilled to welcome CuraSen Therapeutics as the newest member of its Critical Path for Parkinson’s Consortium.
July 26, 2018 First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trials FOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 kissyblack@lotosnile.com Tucson, AZ — July 26, 2018 – The Criti
May 18, 2018 “Improving Clinical Trials to Deliver Better Treatments,” as featured in the Spring 2018 edition of “Progress, the research magazine of Parkinson’s UK”
April 28, 2018 Dr. Stephenson’s presentation at University of Texas Health, San Antonio, The Perry and Ruby Stevens Parkinson’s Disease Center of Excellence: “Critical Path for Parkinson’s Collaboration to Enable Patient Focused Drug Development and Precision Medicine”
July 28, 2017 Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson’s Disease Clinical Trials: A Disease Progression Modeling Analysis Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K,
